UK Clinical Trial Numbers Still ‘Buoyant’ After Brexit
MHRA Transformation Will 'Reshape And Reskill' Workforce
In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.
